RT Journal Article
SR Electronic
T1 WHotLAMP: A simple, inexpensive, and sensitive molecular test for the detection of SARS-CoV-2 in saliva
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21259050
DO 10.1101/2021.06.17.21259050
A1 Ng, David
A1 Pinharanda, Ana
A1 Vogt, Merly C.
A1 Litwin-Kumar, Ashok
A1 Stearns, Kyle
A1 Thopte, Urvashi
A1 Cannavo, Enrico
A1 Enikolopov, Armen
A1 Fiederling, Felix
A1 Kosmidis, Stylianos
A1 Noro, Barbara
A1 Rodrigues-Vaz, Inês
A1 Shayya, Hani
A1 Andolfatto, Peter
A1 Peterka, Darcy S.
A1 Tabachnik, Tanya
A1 D’Armiento, Jeanine
A1 Goldklang, Monica
A1 Bendesky, Andrés
YR 2021
UL http://medrxiv.org/content/early/2021/06/20/2021.06.17.21259050.abstract
AB Despite the development of effective vaccines against SARS-CoV-2, epidemiological control of the virus is still challenging due to slow vaccine rollouts, incomplete vaccine protection to current and emerging variants, and unwillingness to get vaccinated. Therefore, frequent testing of individuals to identify early SARS-CoV-2 infections, contact-tracing and isolation strategies remain crucial to mitigate viral spread. Here, we describe WHotLAMP, a rapid molecular test to detect SARS-CoV-2 in saliva. WHotLAMP is simple to use, highly sensitive (3.6 viral RNA copies per microliter of saliva) and specific, as well as inexpensive, making it ideal for frequent screening. Moreover, WHotLAMP does not require harsh chemicals or specialized equipment and thus can be performed in point-of-care settings, and may also be adapted for resource-limited environments or home use. While applied here to SARS-CoV-2, WHotLAMP can be easily modified to detect other pathogens, making it adaptable for other diagnostic assays, including for use in future outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Friends of the Zuckerman Institute and Columbia University and NIH grant GM112758 to Peter Andolfatto. No authors received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Columbia University IRB AAAT1974All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author.